Grifols SA Ordinary Shares - Class A OZTA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if OZTA is a good fit for your portfolio.
News
-
Grifols shares rebound after KPMG greenlights accounts in wake of short-seller's report
-
Grifols' shares plunge further on short-seller's new report
-
Grifols Shares Rise on $1.76 Billion Sale of 20% Stake in Shanghai RAAS to Pay Down Debt
-
Grifols Shares Rise on Potential Sale of Shanghai RAAS Stock for $1.5 Billion
Trading Information
- Previous Close Price
- €9.03
- Day Range
- €9.07–9.07
- 52-Week Range
- €6.66–34.23
- Bid/Ask
- €0.00 / €0.00
- Market Cap
- €6.16 Bil
- Volume/Avg
- 0 / —
Key Statistics
- Price/Earnings (Normalized)
- 38.17
- Price/Sales
- 0.94
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 23,737
- Website
- https://www.grifols.com
Competitors
Valuation
Metric
|
OZTA
|
4502
|
CSL
|
---|---|---|---|
Price/Earnings (Normalized) | 38.17 | 15.69 | 29.83 |
Price/Book Value | 1.06 | 0.89 | 5.54 |
Price/Sales | 0.94 | 1.54 | 6.63 |
Price/Cash Flow | 10.67 | 7.51 | 34.62 |
Price/Earnings
OZTA
4502
CSL
Financial Strength
Metric
|
OZTA
|
4502
|
CSL
|
---|---|---|---|
Quick Ratio | 0.63 | 0.46 | 0.95 |
Current Ratio | 2.79 | 1.06 | 2.15 |
Interest Coverage | 1.31 | 1.93 | 7.21 |
Quick Ratio
OZTA
4502
CSL
Profitability
Metric
|
OZTA
|
4502
|
CSL
|
---|---|---|---|
Return on Assets (Normalized) | 1.30% | 2.86% | 8.11% |
Return on Equity (Normalized) | 4.69% | 6.13% | 18.17% |
Return on Invested Capital (Normalized) | 3.45% | 4.78% | 10.94% |
Return on Assets
OZTA
4502
CSL
Drug Manufacturers - General Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Eli Lilly and Co
LLY
| Mmlbglgm | Nzv | $834.9 Bil | |||
Johnson & Johnson
JNJ
| Tffylryj | Yyyz | $350.3 Bil | |||
Merck & Co Inc
MRK
| Cvwqvyd | Rccrc | $327.9 Bil | |||
AbbVie Inc
ABBV
| Zlmsngnh | Dwwl | $297.7 Bil | |||
AstraZeneca PLC ADR
AZN
| Qvctpcjrfd | Kzxrb | $247.3 Bil | |||
Roche Holding AG ADR
RHHBY
| Scqvryhqvd | Pqm | $223.9 Bil | |||
Novartis AG ADR
NVS
| Xxpcspkv | Mxl | $216.8 Bil | |||
Amgen Inc
AMGN
| Zxqxcqmwz | Pvtfr | $160.2 Bil | |||
Pfizer Inc
PFE
| Vyvbkcpp | Wxb | $156.0 Bil | |||
Sanofi SA ADR
SNY
| Rjldhmsmb | Czmh | $116.1 Bil |